Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00881920 Phase I CAR.k.28 cells Cyclophosphamide + Fludarabine Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL (CHARKALL) Recruiting USA 0
NCT01084252 Phase Ib/II Isatuximab Dexamethasone + Isatuximab Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies Active, not recruiting USA | ITA | FRA | ESP | BEL 12
NCT01087294 Phase I Anti-CD19 CAR T cells Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation Active, not recruiting USA 0
NCT01109069 Phase II Ibrutinib Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia Completed USA 0
NCT01193842 Phase Ib/II Vorinostat Cyclophosphamide + Doxorubicin + Etoposide + Methylprednisolone + Rituximab + Vincristine Sulfate Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas Completed USA 0
NCT01307267 Phase I Rituximab + Utomilumab Utomilumab A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab Completed USA | ITA | FRA 2
NCT01695941 Phase I Alisertib + Bortezomib + Rituximab Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma Active, not recruiting USA 0
NCT01742988 Phase Ib/II Bendamustine + CUDC-907 + Rituximab CUDC-907 + Rituximab CUDC-907 CUDC-907 + Venetoclax Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma Completed USA 0
NCT01799889 Phase II Entospletinib A Phase 2 of Entospletinib in Subjects With Relapsed or Refractory Hematologic Malignancies Terminated USA | CAN 0
NCT01853631 Phase I Anti-CD19 CAR T cells Cyclophosphamide + Fludarabine Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) Recruiting USA 0
NCT01859819 Phase II Cytarabine + Rituximab Treatment for Advanced B-Cell Lymphoma Completed USA 0
NCT01976585 Phase Ib/II CDX-301 + Poly ICLC In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy Recruiting USA 0
NCT02006485 Phase I Ublituximab + Umbralisib Ibrutinib Ublituximab in Combination With TGR-1202 in Patients With B-cell Malignancies Completed USA 0
NCT02018861 Phase I Itacitinib Itacitinib + Parsaclisib Bendamustine Rituximab Carboplatin + Etoposide + Ifosfamide Parsaclisib A Phase 1, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 Monotherapy and in Combination With INCB039110 in Subjects With Previously Treated B-Cell Malignancies Completed USA 0
NCT02106091 Phase I AFM11 Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL Terminated USA | DEU 2
NCT02153580 Phase I Etoposide Cyclophosphamide + Fludarabine Bendamustine Cellular Immunotherapy Following Cyclophosphamide in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia or B-Cell Prolymphocytic Leukemia Active, not recruiting USA 0
NCT02199184 Phase II Cyclophosphamide + Doxorubicin + Etoposide + Ofatumumab + Prednisone + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Vincristine Sulfate Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia Active, not recruiting USA 0
NCT02207062 Phase I Ibrutinib Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma Active, not recruiting USA 0
NCT02213913 Phase Ib/II Lenalidomide Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Vincristine Sulfate Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas Active, not recruiting USA 0
NCT02253992 Phase Ib/II Nivolumab + Urelumab Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkins Lymphoma Terminated USA | FRA | ESP | DEU 0
NCT02254772 Phase Ib/II Ipilimumab + SD-101 TLR9 Agonist SD-101, Ipilimumab, and Radiation Therapy in Treating Patients With Low-Grade Recurrent B-cell Lymphoma Completed USA 0
NCT02266147 Phase Ib/II SD-101 Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma Terminated USA 0
NCT02272686 Phase II Ibrutinib Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma Terminated USA 0
NCT02290951 Phase I Rituximab Odronextamab Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies Recruiting USA | FRA | DEU 0
NCT02315612 Phase I Anti-CD22 CAR T cells Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies Recruiting USA 0
NCT02328014 Phase Ib/II ACP-319 Acalabrutinib ACP-196 in Combination With ACP-319, for Treatment of B-Cell Malignancies Active, not recruiting USA 0
NCT02343120 Phase I Zanubrutinib Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies Completed USA | ITA 4
NCT02393157 Phase II Carboplatin + Etoposide + Ifosfamide + Obinutuzumab Cytarabine Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL (O-ICE) Recruiting USA 0
NCT02395601 Phase I CPI-1205 A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas Completed USA 0
NCT02436707 Phase II Ibrutinib Cisplatin + Dexamethasone + Gemcitabine + Rituximab Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma Recruiting CAN 0
NCT02443077 Phase III Cyclophosphamide Carmustine + Cytarabine + Etoposide + Melphalan Ibrutinib Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Recruiting USA 1
NCT02457598 Phase I Entospletinib + Tirabrutinib Tirabrutinib Idelalisib + Obinutuzumab + Tirabrutinib Entospletinib + Obinutuzumab + Tirabrutinib Idelalisib + Tirabrutinib Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies Active, not recruiting USA | FRA 1
NCT02500407 Phase I Atezolizumab + Mosunetuzumab A Safety and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) Recruiting USA | FRA | ESP | DEU | CAN 3
NCT02543879 Phase I FT-1101 Azacitidine + FT-1101 Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies Completed USA 0
NCT02569476 Phase I Obinutuzumab + Zanubrutinib BGB 3111 in Combination With Obinutuzumab in Subjects With B-Cell Lymphoid Malignancies Completed USA 2
NCT02600897 Phase Ib/II Lenalidomide + Rituximab Lenalidomide + Obinutuzumab Lenalidomide + Polatuzumab vedotin-piiq + Rituximab Lenalidomide + Obinutuzumab + Polatuzumab vedotin-piiq A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Completed USA | ESP 1
NCT02611323 Phase Ib/II Polatuzumab vedotin-piiq + Rituximab + Venetoclax Obinutuzumab + Polatuzumab vedotin-piiq + Venetoclax A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) Active, not recruiting USA | ITA 1
NCT02624986 Phase Ib/II Idasanutlin + Obinutuzumab A Study of Obinutuzumab With Idasanutlin in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) Terminated USA | DEU 3
NCT02628405 Phase Ib/II Carboplatin + Etoposide + Ifosfamide + Lenalidomide + Rituximab R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma Active, not recruiting USA 0
NCT02631044 Phase I Lisocabtagene maraleucel Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) Recruiting USA 0
NCT02693535 Phase II Cobimetinib + Vemurafenib Atezolizumab + Talazoparib Regorafenib Larotrectinib Trastuzumab + Tucatinib Ipilimumab + Nivolumab Palbociclib Afatinib Entrectinib Talazoparib Pembrolizumab Temsirolimus Pertuzumab + Trastuzumab Atezolizumab + Pertuzumab/trastuzumab/hyaluronidase-zzxf Crizotinib Abemaciclib Sunitinib Olaparib TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR) Recruiting USA 0
NCT02706405 Phase I Cyclophosphamide + Durvalumab + JCAR014 JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Terminated USA 0
NCT02715843 Expanded access MT-3724 Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma No longer available USA 0
NCT02733042 Phase Ib/II Rituximab Durvalumab + Lenalidomide + Rituximab Bendamustine + Durvalumab + Rituximab Durvalumab + Ibrutinib Durvalumab A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia (FUSION NHL 001) Active, not recruiting USA | ITA | FRA | DEU 3
NCT02846935 Phase 0 Decitabine + Tetrahydrouridine p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies Completed USA 0
NCT02875002 Phase I Belinostat + Volasertib Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas Withdrawn USA 0
NCT02898259 Phase Ib/II Ixazomib + Lenalidomide + Rituximab Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma Active, not recruiting USA 0
NCT02914938 Phase I zandelisib Rituximab + zandelisib A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma Recruiting USA 1
NCT02924402 Phase I XmAb13676 Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies Recruiting USA | FRA 0
NCT02950220 Phase I Ibrutinib + Pembrolizumab Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Completed USA 0
NCT02973113 Phase I EB-VST cells + Nivolumab Nivolumab With Epstein Barr Virus Specific T Cells (EB-VSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE) (PREVALE) Completed USA 0
NCT02992522 Phase I Lenalidomide + Obinutuzumab + Venetoclax Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Active, not recruiting USA 0
NCT02997761 Phase II Blinatumomab + Ibrutinib Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia Recruiting USA 0
NCT03019640 Phase II Carmustine + Cytarabine + Etoposide + Filgrastim + Lenalidomide + Melphalan + Rituximab Immunotherapy With Ex Vivo-Expanded Cord Blood-Derived NK Cells Combined With Rituximab High-Dose Chemotherapy and Autologous Stem Cell Transplant for B-Cell Non-Hodgkin's Lymphoma Completed USA 0
NCT03028103 Phase I Fluconazole + Tazemetostat Omeprazole + Repaglinide + Tazemetostat Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, the Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and the Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma Subjects Completed USA 0
NCT03036904 Phase I Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Venetoclax + Vincristine Sulfate Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas (V+DA-EPOCH-R) Active, not recruiting USA 0
NCT03038672 Phase II Nivolumab + Varlilumab Nivolumab Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas Suspended USA 0
NCT03085173 Phase I EGFRt/19-28z/4-1BBL CAR T cells A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies Active, not recruiting USA 0
NCT03103971 Phase I Cyclophosphamide + Fludarabine + HuJCAR014 huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia Recruiting USA 0
NCT03129828 Phase Ib/II Bortezomib + Cyclophosphamide + Doxorubicin + Ibrutinib + Prednisone + Rituximab + Vincristine Sulfate Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI >= 2 (ImbruVeRCHOP) Recruiting DEU 0
NCT03133221 Phase II Idelalisib 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation Active, not recruiting USA 0
NCT03153462 Expanded access axicabtagene ciloleucel + Cyclophosphamide + Fludarabine Axicabtagene Ciloleucel Expanded Access Study Approved for marketing USA 0
NCT03217253 Phase I Tazemetostat Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction Withdrawn USA 0
NCT03223610 Phase I Ibrutinib + Lenalidomide + Obinutuzumab + Prednisone + Venetoclax Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma Recruiting USA 0
NCT03263026 Phase III Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Enzastaurin Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1 Active, not recruiting USA 1
NCT03274492 Phase III Polatuzumab vedotin-piiq Cyclophosphamide + Doxorubicin + Prednisone + Rituximab Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT 15
NCT03277729 Phase Ib/II CD20 CAR T-cells + Cyclophosphamide + Fludarabine A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas Recruiting USA 0
NCT03287817 Phase Ib/II Pembrolizumab Cyclophosphamide + Fludarabine CD19/CD22 CAR T cells CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma (ALEXANDER) Active, not recruiting USA 1
NCT03310619 Phase Ib/II Durvalumab + Lisocabtagene maraleucel A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (PLATFORM) Recruiting USA 0
NCT03328078 Phase I CA-4948 A Study of CA-4948 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Active, not recruiting USA 0
NCT03410901 Phase I BMS-986178 + SD-101 TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas Active, not recruiting USA 0
NCT03424603 Phase I STRO-001 Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies Recruiting USA 0
NCT03483103 Phase II Lisocabtagene maraleucel Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006) Active, not recruiting USA 0
NCT03484702 Phase II Lisocabtagene maraleucel Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects With Aggressive B-Cell Non-Hodgkin Lymphoma (TRANSCENDWORLD) Active, not recruiting ITA | FRA | ESP | DEU | BEL | AUT 5
NCT03488251 Phase II Gemcitabine + MT-3724 + Oxaliplatin PK,PD, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma Terminated USA 0
NCT03570892 Phase III Lenalidomide Ibrutinib Carboplatin + Etoposide + Ifosfamide + Rituximab Carmustine + Cytarabine + Etoposide + Melphalan Cisplatin + Dexamethasone + Gemcitabine + Rituximab Cyclophosphamide + Fludarabine + Tisagenlecleucel Cisplatin + Cytarabine + Dexamethasone + Rituximab Gemcitabine + Oxaliplatin + Rituximab Bendamustine + Fludarabine + Tisagenlecleucel Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (BELINDA) Active, not recruiting USA | ITA | FRA | ESP | DEU | BEL | AUT 11
NCT03573310 Phase I JNJ-64619178 A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS Active, not recruiting USA | ESP | DEU | CAN 1
NCT03579927 Phase Ib/II Filgrastim iC9-CAR.19-IL15-Transduced CB-NK Carmustine + Cytarabine + Etoposide + Melphalan + Rituximab CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma Withdrawn USA 0
NCT03589469 Phase II Loncastuximab tesirine-lpyl Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Active, not recruiting USA | ITA 2
NCT03602157 Phase I ATLCAR.CD30.CCR4 cells Bendamustine + Fludarabine ATLCAR.CD30 cells + ATLCAR.CD30.CCR4 cells Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL Recruiting USA 0
NCT03605589 Phase I Blinatumomab + Pembrolizumab Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma Withdrawn USA 0
NCT03620578 Phase II Cyclophosphamide + Doxorubicin + Etoposide + Nivolumab + Prednisone + Rituximab + Vincristine Sulfate DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL (HO152) Active, not recruiting BEL 1
NCT03625037 Phase Ib/II Epcoritamab GEN3013 Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma Recruiting USA | ITA | FRA | ESP | DEU | CAN 9
NCT03645395 Phase II Lenalidomide + MT-3724 PK,PD, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_003) Terminated USA 0
NCT03671590 Phase I Edralbrutinib Edralbrutinib + Ublituximab + Umbralisib Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies Recruiting 2
NCT03684980 Phase I Glucarpidase + Leucovorin + Methotrexate + Rituximab LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma - ARM A Recruiting USA 0
NCT03696784 Phase I Rimiducid Bendamustine + Fludarabine + iC9-CAR.19-IL15-Transduced CB-NK Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma Recruiting USA 0
NCT03704298 Phase Ib/II axicabtagene ciloleucel + Utomilumab Cyclophosphamide + Fludarabine Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma (ZUMA-11) Active, not recruiting USA 0
NCT03704714 Phase Ib/II Cyclophosphamide + Doxorubicin + Nivolumab + Prednisone + Rituximab + Vincristine Sulfate Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma Recruiting USA 0
NCT03742258 Phase I Cyclophosphamide + Doxorubicin + Mivavotinib + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma Active, not recruiting USA 0
NCT03744676 Phase II Lisocabtagene maraleucel A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) Active, not recruiting USA 0
NCT03749018 Phase II Cyclophosphamide + Doxorubicin + Etoposide + Nivolumab + Prednisone + Rituximab + Vincristine Sulfate Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma Recruiting USA 0
NCT03755154 Phase I VOB560 Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia Recruiting FRA | ESP 2
NCT03761056 Phase II axicabtagene ciloleucel + Cyclophosphamide + Fludarabine Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma (ZUMA-12) Active, not recruiting USA | FRA | CAN 1
NCT03778073 Phase I Cosibelimab Study of TG-1501 in Subjects With Relapsed or Refractory Lymphoma Recruiting USA 0
NCT03793140 Phase II CPI-613 A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations Recruiting USA 0
NCT03804996 Phase I TG-1801 + Ublituximab TG-1801 Study of TG-1801 in Subjects With B-Cell Lymphoma Recruiting 1
NCT03833180 Phase I VLS-101 A Phase 1 Dose-Escalation and Cohort-Expansion of VLS-101 in Hematologic Malignancies Recruiting USA 0
NCT03920631 Phase I Nivolumab Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas (MicroBLITZ) Withdrawn USA 0
NCT03922204 Phase I MCLA-145 A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies Recruiting USA | BEL 0
NCT03934814 Phase I TJ011133 Pembrolizumab + TJ011133 Rituximab + TJ011133 Study of TJ011133 Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma Recruiting USA 1
NCT03990961 Phase II Pembrolizumab Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL) Recruiting USA 0
NCT03995147 Phase II Cyclophosphamide + Doxorubicin + Pembrolizumab + Prednisone + Rituximab + Vincristine Sulfate Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma Recruiting USA 0
NCT04023071 Phase I Aldesleukin + Cyclophosphamide + Fludarabine + FT516 + Obinutuzumab Aldesleukin + Cyclophosphamide + Fludarabine + FT516 + Rituximab Aldesleukin + Cyclophosphamide + Fludarabine + FT516 FT516 in Subjects With Advanced Hematologic Malignancies Recruiting USA 0
NCT04045028 Phase I Tiragolumab Daratumumab + Tiragolumab Rituximab + Tiragolumab A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Recruiting USA 1
NCT04074330 Phase Ib/II Rituximab + TAK-981 A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma Recruiting USA | ITA | FRA | ESP | DEU | CAN 3
NCT04074746 Phase I Cyclophosphamide + Fludarabine AFM13 Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas Recruiting USA 0
NCT04088864 Phase I Anti-CD22 CAR T cells Cyclophosphamide + Fludarabine CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies Enrolling by invitation USA 0
NCT04094311 Phase III Tisagenlecleucel Study of Out of Specification for Tisagenlecleucel Recruiting CAN 1
NCT04160195 Phase I Cyclophosphamide + Fludarabine Anti-CD19-CD20 CAR T cells T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma Terminated USA 0
NCT04161118 Phase II huCART19 TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma (TIGER-CTL019) Active, not recruiting DEU 0
NCT04161248 Phase I Cisplatin + Dexamethasone + Gemcitabine + Rituximab + Venetoclax Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Recruiting CAN 0
NCT04170283 Phase III Zanubrutinib Long-term Extension Study of Zanubrutinib (BGB-3111) in Patients With B-cell Malignancies Enrolling by invitation USA | ITA | FRA | ESP | DEU 9
NCT04205838 Phase II Anakinra + axicabtagene ciloleucel + Cyclophosphamide + Fludarabine Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma Suspended USA 0
NCT04210219 Phase I JNJ-64264681 A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Recruiting USA 6
NCT04214886 Phase I CD19-CD34 CAR transduced T cells + Cyclophosphamide + Fludarabine CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies Recruiting USA 0
NCT04220008 Phase II Busulfan + Clofarabine + Cyclophosphamide + Gemcitabine + Mycophenolate mofetil + Rituximab + Tacrolimus + Vorinostat Busulfan + Clofarabine + Cyclophosphamide + Gemcitabine + Mycophenolate mofetil + Tacrolimus + Vorinostat Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma Not yet recruiting USA 0
NCT04231747 Phase I CC-97540 A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Recruiting USA | CAN 0
NCT04231877 Phase I Cyclophosphamide + Doxorubicin + Etoposide + Filgrastim + Polatuzumab vedotin-piiq + Prednisone + Rituximab Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma Recruiting USA 0
NCT04245722 Phase I Cyclophosphamide + Fludarabine + FT596 + Obinutuzumab Cyclophosphamide + Fludarabine + FT596 Cyclophosphamide + Fludarabine + FT596 + Rituximab FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies Recruiting USA 0
NCT04257578 Phase Ib/II Acalabrutinib + axicabtagene ciloleucel Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma Recruiting USA 0
NCT04263584 Phase II Copanlisib + Cyclophosphamide + Doxorubicin + Prednisolone + Rituximab + Vincristine Sulfate Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL (COPA-R-CHOP) Recruiting DEU 0
NCT04285268 Phase II Bortezomib + Rituximab + Venetoclax Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Withdrawn USA 0
NCT04314843 Phase Ib/II axicabtagene ciloleucel + Lenzilumab Cyclophosphamide + Fludarabine Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma (ZUMA-19) Active, not recruiting USA 0
NCT04331119 Phase II Duvelisib Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell and Indolent B-Cell Lymphomas Recruiting USA 0
NCT04358458 Phase Ib/II GEN3009 First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas Recruiting USA | FRA | ESP | BEL 3
NCT04384484 Phase III Loncastuximab tesirine-lpyl + Rituximab Gemcitabine + Oxaliplatin + Rituximab Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (LOTIS 5) Recruiting USA | FRA | ESP | CAN | BEL 5
NCT04442022 Phase II Cisplatin + Dexamethasone + Gemcitabine + Rituximab Cisplatin + Dexamethasone + Gemcitabine + Rituximab + Selinexor A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Recruiting USA | ITA | ESP | AUT 3
NCT04464798 Phase I Iberdomide Iberdomide + Obinutuzumab Iberdomide + Rituximab A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas Recruiting USA | ITA | FRA | DEU 2
NCT04502706 Phase I FSI-189 FSI-189 + Rituximab Study of FSI-189 as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin Lymphoma Terminated USA 0
NCT04509700 Phase II Parsaclisib Itacitinib + Parsaclisib Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) Recruiting USA | ITA | FRA | ESP | BEL 1
NCT04531046 Phase II axicabtagene ciloleucel Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation Recruiting FRA | BEL 0
NCT04535102 Phase II Bendamustine + Polatuzumab vedotin-piiq + Rituximab POLA+BR for Relapsed or Refractory DLBCL Withdrawn 0
NCT04540796 Phase I JNJ-75348780 A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) Recruiting USA | FRA | ESP 6
NCT04546620 Phase II Cyclophosphamide + Doxorubicin + Prednisolone + Rituximab + Vincristine Sulfate Acalabrutinib + Cyclophosphamide + Doxorubicin + Prednisolone + Rituximab + Vincristine Sulfate Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL) (REMoDL-A) Recruiting 1
NCT04548648 Phase II Acalabrutinib Isavuconazole LCCC1841: A Phase 2 Trial of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas Recruiting USA 0
NCT04555811 Phase I FT596 + Rituximab FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL Recruiting USA 0
NCT04572763 Phase Ib/II Copanlisib + Venetoclax Copanlisib Plus Venetoclax in R/R DLBCL Recruiting USA 0
NCT04578600 Phase I Azacitidine + Lenalidomide + Obinutuzumab CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma Recruiting USA 0
NCT04594642 Phase I TNB-486 A Study of TNB-486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Recruiting USA 1
NCT04594798 Phase II Cyclophosphamide + Doxorubicin + Polatuzumab vedotin-piiq + Prednisone + Rituximab A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL Recruiting USA 0
NCT04599634 Phase I Hu5F9-G4 + Obinutuzumab + Venetoclax Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies Recruiting USA 0
NCT04608487 Phase I Cyclophosphamide + Fludarabine axicabtagene ciloleucel Axi-cel in CNS Lymphoma Recruiting USA 0
NCT04657224 Phase I JNJ-64264681 + JNJ-67856633 A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Recruiting USA | FRA | ESP | BEL 9
NCT04665765 Phase II Polatuzumab vedotin-piiq Carboplatin + Etoposide + Ifosfamide + Polatuzumab vedotin-piiq + Rituximab Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Recruiting USA 0
NCT04739813 Phase I Ibrutinib + Lenalidomide + Obinutuzumab + Polatuzumab vedotin-piiq + Prednisone + Venetoclax Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma Recruiting USA 0
NCT04799275 Phase II Azacitidine + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma Recruiting USA 0
NCT04809467 Phase Ib/II Parsaclisib + Tafasitamab-cxix A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) (topMIND) Recruiting USA | ITA | FRA | ESP | DEU | BEL | AUT 0
NCT04824092 Phase III Cyclophosphamide + Doxorubicin + Lenalidomide + Prednisone + Rituximab + Tafasitamab-cxix + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients (frontMIND) Recruiting USA | ITA | FRA | ESP | DEU | CAN | AUT 21
NCT04830137 Phase I NX-2127 A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies Recruiting USA 0
NCT04833114 Phase III Carboplatin + Etoposide + Ifosfamide + Rituximab Carboplatin + Etoposide + Ifosfamide + Polatuzumab vedotin-piiq + Rituximab Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL) (Pola-R-ICE) Recruiting ESP | DEU | AUT 1
NCT04836195 Phase I PCLX-001 Phase I Trial of PCLX-001 in B-cell Non-Hodgkin Lymphoma and Advanced Solid Malignancies Recruiting CAN 0
NCT04842877 Phase II DS-3201b Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma Recruiting FRA | BEL 0
NCT04855253 Phase Ib/II E7777 Study of E7777 Prior to Kymriah for R/R DLBCL Recruiting USA 0
NCT04882163 Phase Ib/II Cisplatin + Dexamethasone + Gemcitabine + Iberdomide + Rituximab Lenalidomide + Tafasitamab-cxix Iberdomide + Polatuzumab vedotin-piiq + Rituximab Iberdomide + Tafasitamab-cxix Bendamustine + Polatuzumab vedotin-piiq + Rituximab Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma Withdrawn USA | FRA | ESP | BEL | AUT 3
NCT04884035 Phase I CC-99282 + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Iberdomide + Prednisone + Rituximab + Vincristine Sulfate Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphom Recruiting USA | ESP 5
NCT04889716 Phase II Obinutuzumab + RO7082859 Mosunetuzumab CAR-T Followed by Bispecific Antibodies Recruiting USA 0
NCT04914741 Phase Ib/II Cyclophosphamide + Doxorubicin + Prednisolone + Rituximab + RO7082859 + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Polatuzumab vedotin-piiq + Prednisolone + Rituximab + RO7082859 A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL) (COALITION) Recruiting 1
NCT04933617 Phase I Copanlisib + Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Vincristine Sulfate Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas Recruiting USA 0
NCT04974216 Phase II Lenalidomide + Rituximab + Tafasitamab-cxix Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older Recruiting FRA | BEL 0
NCT04975555 Phase II Siltuximab Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy Recruiting USA 0
NCT04980222 Phase II Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + RO7082859 + Vincristine Sulfate A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma Recruiting FRA | ESP 2
NCT05016947 Phase I Dexamethasone + Inotuzumab ozogamicin + Venetoclax Venetoclax Plus Inotuzumab for B-ALL Recruiting USA 0
NCT05024045 Phase I LOXO-305 + LOXO-338 LOXO-338 Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Recruiting USA | FRA 1
NCT05025800 Phase Ib/II Evorpacept + Lenalidomide + Rituximab ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma Recruiting USA 0
NCT05065866 Phase I Azacitidine + Duvelisib Duvelisib in Combination With CC-486 in Lymphoid Malignancy Recruiting USA 0
NCT05075603 Phase I Tisagenlecleucel A Study to Evaluate the Safety, Tolerability and Preliminary Anti-tumor Activity of NT-I7 (Efineptakin Alfa) Post-Tisagenlecleucel (Kymriah) in Relapsed/Refractory Large B-cell Lymphoma Subjects Recruiting USA 0
NCT05171647 Phase III Mosunetuzumab + Polatuzumab vedotin-piiq Mosunetuzumab + Polatuzumab vedotin-piiq + Tocilizumab Gemcitabine + Oxaliplatin + Rituximab A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (SUNMO) Recruiting 2
NCT05202782 Phase II Zanubrutinib Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma Not yet recruiting USA 0
NCT05206357 Phase I Epcoritamab Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab Not yet recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL 8
NCT05207670 Phase II Mosunetuzumab + Tocilizumab A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) Recruiting USA 0
NCT05211336 Phase I Lenalidomide + Nivolumab Ibrutinib + Lenalidomide + Obinutuzumab + Prednisone + Venetoclax Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid With Nivolumab (VIPOR-Nivo) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System Recruiting USA 0
NCT05253495 Phase II Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Hydrocortisone Sodium Succinate + Methotrexate + Rituximab + Vincristine Sulfate Cyclophosphamide + Dexamethasone + Vincristine Sulfate Cytarabine + Etoposide + Polatuzumab vedotin-piiq + Rituximab Cytarabine + Etoposide + Polatuzumab vedotin-piiq Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Hydrocortisone Sodium Succinate + Methotrexate + Polatuzumab vedotin-piiq Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Hydrocortisone Sodium Succinate + Methotrexate + Polatuzumab vedotin-piiq + Rituximab Brentuximab vedotin + Dacarbazine + Doxorubicin + Nivolumab + Rituximab + Vinblastine Brentuximab vedotin + Nivolumab + Rituximab + Vinblastine Brentuximab vedotin + Dacarbazine + Doxorubicin + Nivolumab + Vinblastine Cytarabine + Methotrexate + Rituximab Brentuximab vedotin + Dacarbazine + Doxorubicin + Rituximab + Vinblastine Cyclophosphamide + Doxorubicin + Polatuzumab vedotin-piiq Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma (RADICAL) Recruiting USA 0
NCT05256641 Phase Ib/II Acalabrutinib Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma Not yet recruiting USA 0
NCT05260957 Phase II Mosunetuzumab + Polatuzumab vedotin-piiq CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL). Not yet recruiting USA 0
NCT05270057 Phase I Cyclophosphamide + Doxorubicin + Etoposide + Loncastuximab tesirine-lpyl + Prednisone + Rituximab + Vincristine Sulfate Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies (LONCA) Not yet recruiting USA 0
NCT05272384 Phase I Decitabine and Cedazuridine + Nivolumab Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma Not yet recruiting USA 0
NCT05283720 Phase II Epcoritamab + Lenalidomide Epcoritamab + Ibrutinib + Lenalidomide Cyclophosphamide + Doxorubicin + Epcoritamab + Polatuzumab vedotin-piiq + Prednisone + Rituximab A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma Not yet recruiting USA | FRA | ESP | DEU | CAN 8
NCT05346809 Phase II Isatuximab Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma Recruiting USA 0
NCT05358379 Phase Ib/II CYC140 A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma Recruiting USA 0
NCT05359211 Phase I NKTR-255 Cyclophosphamide + Fludarabine + Lisocabtagene maraleucel NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Not yet recruiting USA 0
NCT05371054 Phase Ib/II Prednisone + Venetoclax + VIP152 Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies Not yet recruiting USA 0